Citations

Clear

4610 citation(s) found for "Lu, Brian".

Regulation of Vps4 ATPase activity by ESCRT-III
Davies, Brian A., Azmi, Ishara F. , Katzmann, David J.

Mayo Clinic

Biochemical Society Transactions | January 22, 2009 | Volume: 37 | Issue: 1 | Pages: 143-145

10.1042/bst0370143 | PMID 19143619 Get It

MVB (multivesicular body) formation occurs when the limiting membrane of an endosome invaginates into the intraluminal space and buds into the lumen, bringing with it a subset of transmembrane cargoes. Exvagination of the endosomal membrane from the cytosol is topologically similar to the budding of retroviral particles and cytokinesis, wherein membranes bud away from the cytoplasm, and the machinery responsible for MVB sorting has been implicated in these phenomena. The AAA (ATPase associated with various cellular activities) Vps4 (vacuolar protein sorting 4) performs a critical function in the MVB sorting pathway. Vps4 appears to dissociate the ESCRTs (endosomal sorting complexes required for transport) from endosomal membranes during the course of MVB sorting, but it is unclear how Vps4 ATPase activity is synchronized with ESCRT release. We have investigated the mechanisms by which ESCRT components stimulate the ATPase activity of Vps4. These studies support a model wherein Vps4 activity is subject to spatial and temporal regulation via distinct mechanisms during MVB sorting.
β-Lactam and Fluoroquinolone Combination Antibiotic Therapy for Bacteremia Caused by Gram-Negative Bacilli
Al‐Hasan, Majdi N. , Wilson, John , Lahr, Brian D. , Thomsen, Kristine M., Eckel‐Passow, Jeanette E. , Vetter, Emily A., Tleyjeh, Imad M. , Hanson, Kristine T. , Baddour, Larry M. , Tleyjeh, Imad M , Hanson, Kristine

Mayo Clinic

Antimicrobial Agents and Chemotherapy | January 22, 2009 | Volume: 53 | Issue: 4 | Pages: 1386-1394

10.1128/aac.01231-08 | PMID 19164144 Get It

ABSTRACT The role of combination antibiotic therapy with a beta-lactam and a fluoroquinolone for bacteremia caused by gram-negative bacilli, to our knowledge, has not been previously described. Much of the previous study of combination therapy has included beta-lactams and aminoglycosides. We conducted a large retrospective cohort study to evaluate 28-day all-cause mortality in patients with monomicrobial bacteremia due to aerobic gram-negative bacilli who received either a combination of beta-lactams and fluoroquinolones or beta-lactam monotherapy. We enrolled adult patients admitted to Mayo Clinic hospitals from 1 January 2001 to 31 October 2006 in the study. After stratification of patients by Pitt bacteremia scores, we used Cox regression models to estimate the hazard ratios (HR) for 28-day all-cause mortality after adjusting for the propensity to receive combination therapy. We identified 398 and 304 unique patients with bacteremia caused by gram-negative bacilli who received single and combination antibiotic therapy, respectively. In less severely ill patients with Pitt bacteremia scores of <4, combination therapy was associated with lower 28-day mortality than single therapy (4.2% [9 of 214] versus 8.8% [28 of 319]; adjusted HR, 0.44; 95% confidence interval [CI], 0.20 to 0.98; P = 0.044). In critically ill patients with Pitt bacteremia scores of ≥4, there was no difference in 28-day mortality between combination and single therapy (25.6% [23 of 90] versus 27.8% [22 of 79]; adjusted HR, 0.87; 95% CI, 0.47 to 1.62; P = 0.660). These findings were consistent for 14-day all-cause mortality. In this large cohort, we found for the first time that combination therapy with beta-lactams and fluoroquinolones was associated with a reduction in 28-day all-cause mortality among less severely ill patients with bacteremia caused by gram-negative bacilli.
Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741
Fuchs, Charles S. , Goldberg, Richard M. , Sargent, Daniel J. , Meyerhardt, Jeffrey A. , Wolpin, Brian M. , Pitot, Henry C., Pollak, Michaël , Green, Erin M. , Sargent, Daniel J , Pollak, Michael N , Meyerhardt, Jeffrey A

Mayo Clinic

Clinical Cancer Research | December 11, 2008 | Volume: 14 | Issue: 24 | Pages: 8263-8269

10.1158/1078-0432.ccr-08-0480 | PMID 19073970 Get It

Abstract Purpose: Insulin-like growth factor (IGF)-I and IGF-II stimulate neoplastic cell growth and inhibit apoptosis, whereas IGF-binding protein-3 (IGFBP-3) inhibits the bioavailability of IGF-I and has independent proapoptotic activity. We examined the influence of baseline plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide on outcome among patients receiving first-line chemotherapy for metastatic colorectal cancer. Experimental Design: The plasma levels of IGF-I, IGF-II, IGFBP-3, and C-peptide as well as data on prognostic factors and body size were measured at baseline among 527 patients participating in a randomized trial of first-line chemotherapy for metastatic colorectal cancer. Results: Higher baseline plasma IGFBP-3 levels were associated with a significantly greater chemotherapy response rate (P = 0.03) after adjusting for other prognostic factors, whereas neither IGF-I nor IGF-II levels significantly predicted tumor response. Higher levels of IGF-I, IGF-II, and IGFBP-3 were all univariately associated with improved overall survival (P = 0.0001 for all). In a model that mutually adjusted for IGF-I and IGFBP-3, as well as other prognostic factors, increasing baseline-circulating IGFBP-3 was associated with a significantly longer time to tumor progression (P = 0.03), whereas circulating IGF-I was not associated with disease progression (P = 0.95). Levels of C-peptide were not associated with any measure of patient outcome. Conclusion: Among colorectal cancer patients receiving first-line chemotherapy, increasing levels of IGFBP-3, an endogenous antagonist to IGF-I, are associated with an improved objective treatment response and a prolonged time to cancer progression. The IGF pathway may represent an important target for future treatment strategies.
Effect of Dehydroepiandrosterone Replacement on Lipoprotein Profile in Hypoadrenal Women
Srinivasan, Manivannan , Irving, Brian A. , Klaus, Katherine A. , Hartman, Stacy, McConnell, Joseph P., Dhatariya, Ketan , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 10, 2008 | Volume: 94 | Issue: 3 | Pages: 761-764

10.1210/jc.2008-1774 | PMID 19066301 Get It

Abstract Context: Levels of dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS) are inversely associated with cardiovascular mortality in men but not women. Very little evidence is available on the impact of DHEA administration on lipoprotein profile in women. DHEAS levels are very low/undetectable in hypoadrenal women. Objective: The objective of the study was to determine the impact of DHEA replacement on lipoprotein profile in hypoadrenal women. Design and Setting: A double-blind, randomized, placebo-controlled, cross-over design study was conducted at the Mayo Clinic. Participants: Thirty-three hypoadrenal Caucasian women (mean ± sd; age 50.3 ± 15.2 yr, body mass index 26.6 ± 4.4 kg/m2) took part in the study. Intervention: Study participants were assigned to receive either a placebo or 50 mg/d of DHEA for 3 months each. Lipid levels and lipoprotein profile were analyzed using the Lipo Science Lipoprotein nuclear magnetic resonance system. Main Outcome Measures: Changes in various lipoprotein sizes and levels were measured. Results: The DHEA period had higher plasma DHEAS levels than during placebo (&lt;0.3 ± 0.0 vs. 3.5 ± 1.3 nmol/liter, P &lt; 0.001). DHEA replacement significantly reduced total cholesterol (20.0 vs. −22, P = 0.02) and high-density lipoprotein (HDL) levels (2.0 vs. −6.0, P = 0.006) and tends to reduce triglyceride and total low-density lipoprotein levels. Although, DHEA replacement had no effect on low-density lipoprotein particle size, it significantly reduced larger HDL particles and to modest extent small HDL particles. Conclusions: Our study findings showed that oral DHEA administration in hypoadrenal women results in an unfavorable lipoprotein profile. The results warrant long-term studies to determine the impact of DHEA replacement on cardiovascular risk.
Polymorphism in theIL18Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women
Palmieri, Rachel T., Wilson, Melanie A., Iversen, Edwin S., Clyde, Merlise A. , Calingaert, Brian , Moorman, Patricia G. , Poole, Charles, Anderson, S. Keith , Beesley, Jonathan, Høgdall, Estrid , Carney, Michael E., Chen, Xiaoqing , Chenevix‐Trench, Georgia , Chang‐Claude, Jenny , Cunningham, Julie M. , DiCioccio, Richard A., Easton, Douglas F. , Edlund, Christopher K., Gayther, Simon A. , Goode, Ellen L. , Goodman, Marc T. , Kjær, Susanne K. , Høgdall, Claus , Hopkins, Michael P., Jenison, Eric L., Blaakær, Jan , Lurie, Galina, McGuire, Valerie, Menon, Usha , Moysich, Kirsten B. , Ness, Roberta B., Pearce, Celeste Leigh , Pike, Malcolm C. , Ramus, Susan J. , Rossing, Mary Anne, Song, Honglin , Terada, Keith Y. , VanDenBerg, David, Vierkant, Robert A. , Wang‐Gohrke, Shan , Webb, Penelope M. , Whittemore, Alice S. , Wu, Anna H. , Schildkraut, Joellen M. , Bowtell, David D.L. , Weber, Rachel Palmieri , Anderson, Alisha R. , Anton‐Culver, Hoda , Brewster, Wendy R. , Doherty, Jennifer A. , Gentry‐Maharaj, Aleksandra , Pharoah, Paul D.P. , Ziogas, Argyrios , Berchuck, Andrew , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 8, 2008 | Volume: 17 | Issue: 12 | Pages: 3567-3572

10.1158/1055-9965.epi-08-0548 | PMID 19064572 Get It

AbstractOver 22,000 cases of ovarian cancer were diagnosed in 2007 in the United States, but only a fraction of them can be attributed to mutations in highly penetrant genes such as BRCA1. To determine whether low-penetrance genetic variants contribute to ovarian cancer risk, we genotyped 1,536 single nucleotide polymorphisms (SNP) in several candidate gene pathways in 848 epithelial ovarian cancer cases and 798 controls in the North Carolina Ovarian Cancer Study (NCO) using a customized Illumina array. The inflammation gene interleukin-18 (IL18) showed the strongest evidence for association with epithelial ovarian cancer in a gene-by-gene analysis (P = 0.002) with a &lt;25% chance of being a false-positive finding (q value = 0.240). Using a multivariate model search algorithm over 11 IL18 tagging SNPs, we found that the association was best modeled by rs1834481. Further, this SNP uniquely tagged a significantly associated IL18 haplotype and there was an increased risk of epithelial ovarian cancer per rs1834481 allele (odds ratio, 1.24; 95% confidence interval, 1.06-1.45). In a replication stage, 12 independent studies from the Ovarian Cancer Association Consortium (OCAC) genotyped rs1834481 in an additional 5,877 cases and 7,791 controls. The fixed effects estimate per rs1834481 allele was null (odds ratio, 0.99; 95% confidence interval, 0.94-1.05) when data from the 12 OCAC studies were combined. The effect estimate remained unchanged with the addition of the initial North Carolina Ovarian Cancer Study data. This analysis shows the importance of consortia, like the OCAC, in either confirming or refuting the validity of putative findings in studies with smaller sample sizes. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3567–72)
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
Ringdén, Olle , Pavletic, Steven Z. , Anasetti, Claudio , Wang, Tao , Antin, Joseph H. , Bartolomeo, Paolo Di , Bolwell, Brian J., Bredeson, Christopher , Cairo, Mitchell S. , Gupta, Vikas , Hahn, Theresa , Hale, Gregory A., Halter, Jörg , Jagasia, Madan , Litzow, Mark R. , Marks, David I. , Cowan, Morton J. , Petersdorf, Effie W. , Russell, James A. , Schiller, Gary J. , Schouten, Harry C. , Verdonck, Leo F. , Horowitz, Mary M. , Arora, Mukta , Barrett, A. John , Wang, Dan , Gale, Robert Peter , Locatelli, Franco , McCarthy, Philip L. , Spellman, Stephen R. , Wingard, John R. , Halter, Joerg , Ringden, Olov , Gupta, Vikas

Mayo Clinic

Blood | December 5, 2008 | Volume: 113 | Issue: 13 | Pages: 3110-3118

10.1182/blood-2008-07-163212 | PMID 19059878 Get It

AbstractDo some patients benefit from an unrelated donor (URD) transplant because of a stronger graft-versus-leukemia (GVL) effect? We analyzed 4099 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) undergoing a myeloablative allogeneic hematopoietic cell transplantation (HCT) from an URD (8/8 human leukocyte antigen [HLA]–matched, n = 941) or HLA-identical sibling donor (n = 3158) between 1995 and 2004 reported to the CIBMTR. In the Cox regression model, acute and chronic GVHD were added as time-dependent variables. In multivariate analysis, URD transplant recipients had a higher risk for transplantation-related mortality (TRM; relative risk [RR], 2.76; P < .001) and relapse (RR, 1.50; P < .002) in patients with AML, but not ALL or CML. Chronic GVHD was associated with a lower relapse risk in all diagnoses. Leukemia-free survival (LFS) was decreased in patients with AML without acute GVHD receiving a URD transplant (RR, 2.02; P < .001) but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML. In patients without GVHD, multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses. In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect.
Measuring Granulocyte and Monocyte Accumulation at Malignant Lymphoma Sites
Weiner, George J. , Link, Brian K. , Horning, Sandra J., Wiseman, Gregory A., Juweid, Malik E. , Link, Brian K , Weiner, George

Mayo Clinic

Journal of Clinical Oncology | November 25, 2008 | Volume: 27 | Issue: 1 | Pages: 154-155

10.1200/jco.2008.19.2393 | PMID 19029411 Get It

Percutaneous Parathyroid Ethanol Ablation in Patients with Multiple Endocrine Neoplasia Type 1
Veldman, Mark W., Reading, Carl C., Farrell, Michael A., Mullan, Brian P., Wermers, Robert A. , Grant, Clive S., Thompson, Geoff B.

Mayo Clinic

American Journal of Roentgenology | November 19, 2008 | Volume: 191 | Issue: 6 | Pages: 1740-1744

10.2214/ajr.07.3431 | PMID 19020245 Get It

Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial
Shaw, Edward G. , Coons, Stephen W., Bullard, Dennis E., Brachman, David, Buckner, Jan C. , Stelzer, K. , Barger, Geoffrey, Brown, Paul D. , Mehta, Minesh P. , Berkey, Brian A. , Gilbert, Mark R. , Mehta, Minesh P

Mayo Clinic

Journal of Neurosurgery | October 31, 2008 | Volume: 109 | Issue: 5 | Pages: 835-841

10.3171/jns/2008/109/11/0835 | PMID 18976072 Get It

Object In 1998, the Radiation Therapy Oncology Group initiated a Phase II study of observation for adults < 40 years old with cerebral low-grade glioma who underwent a neurosurgeon-determined gross-total resection (GTR). Methods Patient eligibility criteria included the presence of a World Health Organization Grade II astrocytoma, oligodendroglioma, or mixed oligoastrocytoma confirmed histologically; age 18–39 years; Karnofsky Performance Scale score ≥ 60; Neurologic Function Scale score ≤ 3; supratentorial tumor location; neurosurgeon-determined GTR; and pre- and postoperative MR imaging with contrast enhancement available for central review by the principal investigator. Patients were observed following GTR and underwent MR imaging every 6 months. Prognostic factors analyzed for their contribution to patient overall survival, progression-free survival (PFS), and tumor recurrence included age, sex, Karnofsky Performance Scale score, Neurologic Function Scale score, histological type, contrast enhancement on preoperative MR imaging, preoperative tumor diameter, residual disease based on postoperative MR imaging, and baseline Mini-Mental State Examination score. Results Between 1998 and 2002, 111 eligible patients were entered into the study. In these 111 patients, the overall survival rates at 2 and 5 years were 99 and 93%, respectively. The PFS rates in these 111 patients at 2 and 5 years were 82 and 48%, respectively. Three prognostic factors predicted significantly poorer PFS in univariate and multivariate analyses: 1) preoperative tumor diameter ≥ 4 cm; 2) astrocytoma/oligoastrocytoma histological type; and 3) residual tumor ≥ 1 cm according to MR imaging. Review of the postoperative MR imaging results revealed that 59% of patients had < 1 cm residual disease (with a subsequent 26% recurrence rate), 32% had 1–2 cm residual disease (with a subsequent 68% recurrence rate), and 9% had > 2 cm residual disease (with a subsequent 89% recurrence rate). Conclusions These data suggest that young adult patients with low-grade glioma who undergo a neurosurgeondetermined GTR have a > 50% risk of tumor progression 5-years postoperatively, warranting close follow-up and consideration for adjuvant treatment.
Mental Illness in Young Adults Who Had Strabismus as Children
Mohney, Brian G., McKenzie, Jeff A., Capo, Jason, Nusz, Kevin J., Mrazek, David A. , Diehl, Nancy N.

Mayo Clinic

Pediatrics | October 31, 2008 | Volume: 122 | Issue: 5 | Pages: 1033-1038

10.1542/peds.2007-3484 | PMID 18977984 Get It

OBJECTIVE. We investigated the prevalence and types of psychiatric disorders diagnosed by early adulthood among patients who had common forms of strabismus as children. METHODS. The medical records of children (&lt;19 years) who were diagnosed as having esotropia (N = 266) or exotropia (N = 141) while residents of Olmsted County, Minnesota, between January 1, 1985, and December 31, 1994, were reviewed retrospectively for psychiatric disease diagnoses. Each case subject was compared with a randomly selected, individually birth- and gender-matched, control subject from the same population. RESULTS. A mental health disorder was diagnosed for 168 (41.3%) of the 407 patients with a history of childhood strabismus, who were monitored to a mean age of 17.4 years, compared with 125 control subjects (30.7%). Children with exotropia were 3.1 times more likely to develop a psychiatric disorder than were control subjects when monitored to a mean age of 20.3 years. Children with esotropia were no more likely to develop mental illness than were control subjects when monitored for similar periods. Patients with intermittent exotropia also were significantly more likely to have greater numbers of mental health disorders, mental health emergency department visits, and mental health hospitalizations and to have suicidal or homicidal ideation. CONCLUSIONS. Children diagnosed as having strabismus in this population, especially those with exotropia, were at increased risk for developing mental illness by early adulthood. Patients with intermittent exotropia seemed to be particularly prone to developing significant psychiatric diseases by the third decade of life.